Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.

ABSTRACT:

Background

The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.

Objectives

To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque psoriasis treated with adalimumab, etanercept or ustekinumab in a large prospective cohort.

Methods

Prospective cohort study examining the comparative risk of major CVEs was conducted using the British Association of Dermatologists Biologics and Immunomodulators Register. The main analysis compared adults with chronic plaque psoriasis receiving ustekinumab with tumour necrosis-α inhibitors (TNFi: etanercept and adalimumab), whilst the secondary analyses compared ustekinumab, etanercept or methotrex

SUBMITTER: Rungapiromnan W 

PROVIDER: S-EPMC7155017 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature